Utah Medical Products (UTMD) Equity Average (2011 - 2026)

Utah Medical Products' Equity Average history runs 16 years deep, the most recent figure standing at $119.8 million for Q1 2026.

• In Q1 2026, Equity Average rose 2.2% year-over-year to $119.8 million; the TTM figure through Mar 2026 stood at $119.8 million (up 2.2% YoY), while the FY2025 annual figure was $118.3 million, down 3.68% from the prior year.
• Equity Average was $119.8 million for Q1 2026 at Utah Medical Products, up from $118.8 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $128.0 million in Q1 2024 to a low of $107.8 million in Q3 2022.
• Historically, Equity Average has averaged $118.2 million across 5 years, with a median of $118.8 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Equity Average climbed 13.82% in 2023, then decreased 8.43% in 2025.
• A 5-year view of Equity Average shows it stood at $111.2 million in 2022, then gained by 13.3% to $126.0 million in 2023, then retreated by 4.12% to $120.8 million in 2024, then declined by 1.7% to $118.8 million in 2025, then increased by 0.89% to $119.8 million in 2026.
• The last three Equity Average figures came in at $119.8 million (Q1 2026), $118.8 million (Q4 2025), and $117.9 million (Q3 2025), per Business Quant data.